RxDoctor Payments Data

James Sabiers, MD

Hematology & Oncology · Dayton, OHNPI 1447205638

Payments from drug & device makers

$383in general payments, 2019–2025

Across 18 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$100
  • E.r. Squibb & Sons, L.L.C.$63
  • Novartis$62
  • Pfizer$49
  • Bristol Myers Squibb$29
  • Pharmacyclics LLC, An Abbvie Company$27
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$17345%
  • Education$21055%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$383 in reported general payments places this provider in the 15th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$89,483
Medicare patients
373
Services billed
1,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib63$1,065,874
BrukinsaZanubrutinib43$643,530
XtandiEnzalutamide40$554,162
RevlimidLenalidomide21$409,876
IbrancePalbociclib25$381,979
TagrissoOsimertinib Mesylate13$218,913
VerzenioAbemaciclib13$194,996
EliquisApixaban114$79,471
VenclextaVenetoclax17$64,883
Imatinib Mesylate24$50,487
Abiraterone Acetate47$15,429
XareltoRivaroxaban11$10,477
Enoxaparin Sodium12$7,058
Ondansetron Hcl94$6,011
Exemestane61$5,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$27$1,065,87463 claims
PfizerIbrance, Eliquis$49$461,450139 claims
Bristol Myers SquibbRevlimid$29$409,87621 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$24$15,42947 claims
Johnson & JohnsonXarelto$100$10,47711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →